L-Carnitine
Brand names: Carnitor, Levocarnil
L-carnitine (levocarnitine) is a naturally occurring amino-acid derivative used to treat primary and certain secondary carnitine deficiency states, including those associated with some inborn errors of metabolism and dialysis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It facilitates transport of long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation and helps remove accumulated acyl groups as acylcarnitines, supporting energy production and detoxification.
Prescribing in practice
- Treatment of inherited metabolic carnitine deficiency should be directed by a specialist metabolic team, as inappropriate use without confirmed deficiency offers no benefit.
- Available in oral and intravenous formulations; gastrointestinal upset and a fishy body odour can occur, more commonly with oral therapy.
- Dose adjustment may be required in renal impairment and in dialysis-associated deficiency; consult the SPC.
Monitoring
Monitor plasma carnitine levels and clinical and biochemical response under specialist supervision, particularly in metabolic disorders.
Counselling the patient
- This replaces a substance your body needs to use fats for energy.
- Some people notice a fishy body odour or stomach upset, which can improve with dose adjustment.
- Do not stop treatment without discussing it with your metabolic team.
Evidence & guidelines
Levocarnitine is an established treatment for primary carnitine deficiency and recognised carnitine-deficiency states, with use guided by specialist metabolic medicine practice.
Reference: TOXBASE; SPC Carnitor; AASLD Valproate Hepatotoxicity Guidance; Neurology Toolbox UK; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- PREVENT Cardiovascular Risk Calculator (AHA 2023) · Cardiovascular Risk
- Osmol Gap · Renal / Metabolic
- BMI + Metabolic Risk Assessment · Obesity
- HOMA-IR — Insulin Resistance · Formula
- Metabolic Syndrome Criteria (IDF 2006) · Diagnosis
- Fibrotic NASH Index (FNI) for NAFLD/NASH Fibrosis Prediction · Liver Disease
- Difficult Airway Algorithm (DAS) · DAS 2015; Royal College of Anaesthetists
- Major Haemorrhage Protocol · NICE NG24; UK MHP guidelines
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines